证券代码：873167 证券简称：新赣江 公告编号：2023-082 江西新赣江药业股份有限公司 第二届董事会第二十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2023 年 8 月 28 日 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯 4.发出董事会会议通知的时间和方式：2023 年 8 月 17 日以书面方式发出 5.会议主持人：董事长张爱江先生 6.会议列席人员：公司高级管理人员 二、议案审议情况 （一）审议通过《关于<2023 年半年度报告及摘要>的议案》 1.议案内容： 根据《北京证券交易所股票上市规则（试行）》《公开发行证券的公司信息 披露内容与格式准则第 54 号—北京证券交易所上市公司中期报告》《关于做好 上市公司 2023 年半年度报告披露相关工作的通知》等相关规定和要求，公司 编制了《2023 年半年度报告》及其摘要。 具体内容详见本公司于 2023 年 8 月 29 日在北京证券交易所 ...

Company Overview - The company was listed on the Beijing Stock Exchange on February 9, 2023[4]. - The total share capital of the company is 70,861,250 shares, with no preferred shares issued[19]. - The actual controllers of the company include Zhang Aijiang and several family members, ensuring a stable management structure[20]. - The company operates primarily in the pharmaceutical manufacturing industry, focusing on chemical raw materials and traditional Chinese medicine[19]. - The company has not faced any delisting risks as per the latest report[10]. Financial Performance - The revenue for the first half of 2023 reached 67,590,000 RMB, with a sales volume of 10,815,000 RMB and total tax contributions of 7,946,000 RMB[4]. - The company achieved operating revenue of ¥123,359,358.17, representing a growth of 19.89% compared to the same period last year[26]. - Net profit attributable to shareholders reached ¥30,480,652.04, an increase of 32.98% year-on-year[26]. - Operating revenue rose by 19.89% to ¥123,359,358.17, compared to ¥102,894,752.83 in the previous year[43]. - Net profit increased by 34.88% to ¥30,826,161.10, compared to ¥22,854,181.63 in the same period last year[43]. - The company's gross profit margin improved to 48.45%, up from 45.58% in the same period last year[26]. - The company's cash flow from operating activities was ¥15,115,039.82, a decrease of 52.75% compared to the previous year[28]. - The company reported a net non-recurring profit of ¥1,861,601.22 after tax[31]. Assets and Liabilities - The total assets of the company amounted to 1.6 billion RMB as of 2022[4]. - Total assets at the end of the reporting period amounted to ¥502,953,543.58, reflecting a growth of 42.13% from the end of the previous year[27]. - Net assets attributable to shareholders increased to ¥455,400,015.67, up 63.52% compared to the previous year-end[27]. - The company's total liabilities decreased to CNY 43,018,266.61 from CNY 71,186,539.18, a reduction of about 39.5%[108]. - The company's equity attributable to shareholders increased to CNY 455,400,015.67 from CNY 278,499,029.84, showing a growth of approximately 63.7%[108]. Research and Development - The company has 206 drug registration approvals and 68 patents, demonstrating its capacity for high-quality drug production[32]. - Research and development expenses grew by 33.65% to ¥5,201,297.60, reflecting the company's commitment to innovation[43]. - The company continues to focus on technological and management innovation to enhance core competitiveness[36]. Market and Product Development - The company's product, Vitamin C Chewable Tablets, was awarded the "Jiangxi Famous Brand Product" by the Jiangxi Brand Construction Promotion Association in June 2023[4]. - The company plans to expand its market presence and enhance its product offerings in the pharmaceutical sector[8]. - The company reported a significant increase in sales for its traditional Chinese medicine products, with sales reaching 22,625,000 RMB in 2022, up from 8,359,000 RMB in 2020[4]. Shareholder Information - The largest shareholder, Zhang Aijiang, holds 34,857,012 shares, representing 49.1905% of the total shares[80]. - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 75.4755%[80]. - The company has not engaged in any significant related party transactions during the reporting period[71]. Corporate Governance - The company has established a comprehensive internal control system to mitigate risks associated with governance and compliance as its operations expand[65]. - The company has maintained a stable management team with no significant changes in directors or independent directors[97]. - The company appointed Cheng Shuping as the new Chief Financial Officer on June 29, 2023[98]. Investment and Fundraising - The company raised a total of RMB 161,358,750.00 through the issuance of 17,075,000 shares at a price of RMB 9.45 per share for the production of traditional Chinese medicine health products[85]. - The total net amount raised from the 2023 public offering is RMB 16,413.56 million, with RMB 2,316.25 million already invested in various projects[89]. - The company has no plans to change the use of raised funds or to supplement working capital with idle funds[88]. Risk Management - The company faces risks related to the transition of raw material drug approvals to a filing system, which may lead to increased competition and potential revenue impact[64]. - Direct materials account for a significant portion of production costs, making the company vulnerable to price fluctuations and supply stability issues[64]. - The company has implemented measures to control product quality risks, including advanced technology and modern management practices[65]. Accounting and Financial Reporting - The company adheres to the accounting standards, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows[157]. - The company has not changed its accounting policies or estimates compared to the previous financial year[141]. - The financial statements reflect the results of subsidiaries from the date control is obtained, with adjustments made to the comparative figures accordingly[171].

证券代码：873167 证券简称：新赣江 公告编号：2023-080 江西新赣江药业股份有限公司 上市公司已于 2022 年 4 月 1 日对上述股票申请限售。详见公司于 2022 年 4 月 1 日披露的《关于股东所持公司股票自愿限售的公 告》。公司于 2023 年 2 月 9 日在北京证券交易所上市。根据《北京证券交易所股票上市规则（试行）》第 2.4.2、2.4.3 条，上述股票 自公司上市之日起 12 个月内不得转让，因此上述股票处于法定限售状态，法定限售期为 2023 年 2 月 9 日至 2024 年 2 月 8 日。 本次股票自愿限售具体为：自法定限售期届满后，转为自愿限售 6 个月，即限售期限由 2024 年 2 月 8 日延长至 2024 年 8 月 8 日。 关于股东所持公司股票自愿限售的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 法律责任。 一、 本次股票自愿限售数量共计 51,213,800 股，占公司总股本 72.27%，涉及自愿 限售股东 7 名。 二、 本次股票自愿限售的明细 ...

2022 年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 说明会类型 江西新赣江药业股份有限公司(以下简称"公司")于 2023 年 4 月 26 日 在北京证券交易所官方信息披露平台((http://www.bse.cn/)发布了《江西新 赣江药业股份有限公司 2022 年年度报告》及《江西新赣江药业股份有限公司 2022 年年度报告摘要》，为方便广大投资者更深入了解公司 2022 年年度经营 业绩的具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告业 绩说明会。 二、 说明会召开的时间、地点 证券代码：873167 证券简称：新赣江 公告编号：2023-051 江西新赣江药业股份有限公司 公司董事会秘书:严棋鹏先生 公司财务负责人:曹爱平先生 公司保荐代表人:顾磊先生 四、 投资者参加方式 本次说明会采用网络方式召开。 （一）会议召开时间：2023 年 5 月 11 日(周四)15:00-17:00。 （二）会议召开地点 会议召开地点本次业绩说明会将 ...

Financial Performance - Net profit attributable to shareholders rose by 27.35% to CNY 16,679,264.59 for the first quarter of 2023[9] - Operating revenue increased by 25.39% to CNY 69,223,571.97 year-on-year[9] - Total operating revenue for Q1 2023 reached ¥69,223,571.97, an increase from ¥55,206,584.18 in Q1 2022, representing a growth of approximately 25.5%[38] - Total revenue for Q1 2023 was CNY 54,998,310.76, compared to CNY 49,831,078.54 in Q1 2022, indicating a growth of about 10.4%[41] - Net profit for Q1 2023 reached CNY 17,163,144.48, compared to CNY 12,923,439.52 in Q1 2022, marking an increase of about 32.5%[39] - The company reported a total comprehensive income of CNY 17,163,144.48 for Q1 2023, compared to CNY 12,923,439.52 in Q1 2022, reflecting an increase of about 32.5%[39] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.29, up from CNY 0.26 in Q1 2022, reflecting an increase of approximately 11.5%[39] Assets and Liabilities - Total assets increased by 44.17% to CNY 510,167,699.87 compared to the end of the previous year[9] - The company's total liabilities decreased to ¥46,180,127.01 from ¥71,186,539.18, a reduction of approximately 35%[32] - The company has a total liability of ¥29,212,343.92 as of March 31, 2023, down from ¥47,750,231.20 at the end of 2022, reflecting a reduction in financial obligations[36] - The company's equity increased from ¥51,225,000.00 to ¥70,861,250.00, showing a growth of around 38%[32] - Shareholders' equity totaled ¥465,620,651.14 as of March 31, 2023, up from ¥285,701,188.30 at the end of 2022, indicating a growth of about 63.0%[37] Cash Flow - Cash flow from operating activities decreased by 115.99% to CNY -2,711,385.11 due to increased tax payments and employee wages[11] - The net cash flow from operating activities for Q1 2023 was negative at CNY -2,711,385.11, a significant decrease from CNY 16,952,900.64 in Q1 2022[43] - The net cash flow from investment activities was 24,209,242.95 CNY, compared to a negative cash flow of -316,139.27 CNY in the previous year[44] - The total cash inflow from financing activities amounted to 172,488,630.84 CNY, while cash outflow was 3,511,500.00 CNY, resulting in a net cash flow of 168,977,130.84 CNY[44] - The net increase in cash and cash equivalents for the period was 190,474,988.68 CNY, leading to a closing balance of 248,335,743.27 CNY[44] - Cash and cash equivalents as of March 31, 2023, were ¥206,900,163.02, significantly higher than ¥42,661,323.90 at the end of 2022, showing improved liquidity[35] Shareholder Information - The number of ordinary shareholders increased to 4,337, reflecting a growing investor interest[15] - The largest shareholder, Zhang Aijiang, holds 34,857,012 shares, representing 49.19% of total shares[17] - Zhang Ming is the second-largest shareholder with 4,980,946 shares, accounting for 7.03%[17] - The total shares held by the top ten shareholders amount to 53,482,928, which is 75.48% of the total[18] Expenses and Costs - Sales expenses increased by 74.14% due to higher logistics and advertising costs[11] - Total operating costs for Q1 2023 were ¥48,794,022.30, up from ¥39,421,157.99 in Q1 2022, indicating an increase of about 23.5%[38] - Operating costs for Q1 2023 were CNY 26,439,104.07, an increase from CNY 23,998,662.33 in Q1 2022, which is a rise of approximately 10.1%[41] - The company incurred a tax expense of CNY 3,308,216.02 in Q1 2023, compared to CNY 2,311,165.99 in Q1 2022, which is an increase of approximately 43.2%[39] Commitments and Compliance - The company has committed to repurchase shares and compensate investors due to false statements, which is currently being fulfilled[24] - The company has also committed to avoid fund occupation and is in compliance with this commitment[24] - The company has made commitments to reduce and regulate related party transactions, which are currently being fulfilled[24] - The company is currently fulfilling its lock-up commitments made on March 16, 2022[22] Other Information - The company has no ongoing litigation or arbitration matters during the reporting period[21] - There are no external guarantees or loans provided by the company[21] - The company has not engaged in any significant related party transactions during the reporting period[21] - There are no assets under seizure, detention, or freezing[21] - The company has not been subject to any investigations or penalties[21] - The company has not executed any share repurchase plans during the reporting period[21] - The company reported a decrease in accounts payable from ¥15,099,488.18 in Q1 2022 to ¥12,975,603.62 in Q1 2023, suggesting improved payment practices[36] - Research and development expenses for Q1 2023 were ¥2,593,476.93, slightly higher than ¥2,358,891.29 in Q1 2022, indicating continued investment in innovation[38] - The increase in long-term equity investments from ¥22,474,586.75 at the end of 2022 to ¥65,883,184.13 as of March 31, 2023, indicates a strategic focus on expanding investment portfolios[35]

Recognition and Awards - The company was awarded the title of "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration in October 2022[3]. - In November 2022, the company was recognized as a "High-tech Enterprise" by the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial Department of Finance, and the State Taxation Administration Jiangxi Provincial Taxation Bureau[4]. - The company is recognized as a "high-tech enterprise" and has achieved provincial-level recognition for its specialized and innovative capabilities[47]. Financial Performance - The company's operating revenue for 2022 was CNY 211,150,421.69, representing a year-on-year increase of 1.56% compared to CNY 207,913,346.74 in 2021[28]. - The net profit attributable to shareholders for 2022 was CNY 46,322,272.63, a decrease of 15.50% from CNY 54,830,811.11 in 2021[28]. - The gross profit margin for 2022 was 46.07%, up from 44.02% in 2021[28]. - Total assets increased by 25.47% to CNY 353,875,321.26 at the end of 2022, compared to CNY 282,032,972.79 at the end of 2021[30]. - Total liabilities rose by 56.45% to CNY 71,186,539.18 at the end of 2022, compared to CNY 45,496,463.44 at the end of 2021[30]. - The company's net assets attributable to shareholders increased by 19.95% to CNY 278,499,029.84 at the end of 2022, compared to CNY 232,176,757.21 at the end of 2021[30]. - The basic earnings per share for 2022 was CNY 0.90, down from CNY 1.08 in 2021, reflecting a decrease of 15.50%[28]. - The company's debt-to-asset ratio (consolidated) was 20.12% at the end of 2022, compared to 16.13% at the end of 2021[30]. - The net cash flow from operating activities for 2022 was ¥89,419,311.08, an increase of 90.49% compared to ¥46,941,334.18 in 2021[32]. - The total asset growth rate for 2022 was 25.47%, recovering from a decline of 4.95% in 2021[33]. - The operating profit for 2022 was CNY 53,831,867.72, a decrease of 12.99% year-on-year, while net profit was CNY 46,152,272.73, down 13.33% year-on-year[48]. Risk Management - The company faces risks related to fluctuations in raw material prices, which significantly impact its profitability due to the high proportion of direct materials in production costs[10]. - The company has established a comprehensive internal control system to mitigate risks associated with governance and operational complexities as it expands its production and sales scale[11]. - The company has completed a systematic analysis of major risk factors, with certain risks no longer classified as significant, such as the risk of not fully paying social insurance and housing funds for all employees[12]. - The company has established a strict procurement system to ensure the quality of raw materials, adhering to GMP management standards[40]. - The company has engaged a qualified third-party organization to establish a robust quality control and monitoring system[71]. - The company has implemented a robust fundraising management system to address risks related to the feasibility of investment projects, which are influenced by market conditions and technological developments[138]. Regulatory Environment - The National Development and Reform Commission announced the cancellation of government pricing for drugs, allowing market competition to determine actual transaction prices[59]. - The Drug Administration Law emphasizes fair pricing practices and prohibits price monopolies and fraud in drug pricing[59]. - The implementation of the Drug Registration Management Measures aims to streamline the approval process for new drugs and generics[63]. - The new regulations eliminate GMP and GSP certifications, simplifying the approval process while maintaining high drug quality standards[70]. - The implementation of a drug marketing authorization holder system shifts the primary responsibility for drug quality from manufacturers to the marketing authorization holders[70]. - The new regulatory environment emphasizes a shift from threshold-based management to a focus on regulatory oversight[70]. Research and Development - The company has made significant investments in research and development, although specific figures were not disclosed in the provided content[114]. - R&D expenditure for the current period is ¥8,862,117.87, representing 4.20% of operating income, an increase from 3.95% in the previous period[106]. - The total number of patents owned by the company increased from 40 to 53, with invention patents rising from 5 to 8[109]. - The company is advancing several R&D projects, including the consistency evaluation of Metronidazole tablets and the development of new drugs like Dexamethasone and Acetaminophen, aimed at improving product quality and market competitiveness[110]. - The company is developing new health food products, including enzyme and selenium-rich products, to expand its product line and market presence[112]. Environmental Compliance - The company has been proactive in enhancing its environmental protection measures in response to stricter national standards, which may increase operational costs[11]. - The company has maintained a focus on environmental protection, complying with national laws and regulations, and investing in waste treatment facilities[126]. - The company is preparing for potential future regulatory changes regarding environmental standards, which may increase its environmental compliance costs[126]. - The company faces risks from stricter environmental regulations, which may increase production costs and require further investment in pollution control measures[136]. Shareholder Commitments - The actual controller and major shareholders made a lock-up commitment on March 16, 2022, stating they will not transfer or entrust others to manage their shares for 12 months after the listing of Xin Gan Jiang stock[148]. - The company has committed to strict adherence to promises made during the public offering process, with penalties for non-compliance including public apologies and compensation for investor losses[171]. - The actual controller and major shareholders have pledged to compensate for any losses incurred by the company or investors due to non-fulfillment of commitments, with restrictions on share transfers until obligations are met[172]. - The company has committed to ensuring the accuracy and completeness of its public disclosures, taking legal responsibility for any inaccuracies[181]. Operational Strategies - The company plans to adapt its business strategies to comply with new regulatory requirements and address market competition challenges[13]. - The company aims to strengthen its sales team by recruiting industry sales elites and optimizing the sales system to promote sustainable growth in its main business[132]. - The company intends to leverage capital markets for external expansion, focusing on mergers and acquisitions to enhance its market position and operational scale[132]. - The company is actively expanding its integrated business from raw materials to formulations, focusing on strategic development of unique products such as Duzhong Qiang Bone Capsules and Compound Yinqiao Anmin Capsules[130].

江西省吉安市吉州区云章路 36 号 江西新赣江药业股份有限公司 江西新赣江药业股份有限公司招股说明书 证券简称： 新赣江 证券代码： 873167 保荐人（主承销商） （浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 发行人及全体董事、监事、高级管理人员 ...

证券简称： 新赣江 证券代码： 873167 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐人（主承销商） （浙江省杭州市西湖区天目山路 198 号财通双冠大厦西楼） 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明 其对注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。 任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 声明 江西省吉安市吉州区云章路 36 号 江西新赣江药业股份有限公司 江西新赣江药业股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国 ...